United Therapeutics Corp

United Therapeutics Corp, a Silver Spring, Maryland-based biotechnology manufacturer of specialized pharmaceuticals, operates as a prime contractor delivering pharmaceutical products—chiefly treprostinil inhalation solution (Tyvaso), remodulin injection, orenitram tablets, and unituxin chemotherapy—exclusively to the Department of Veterans Affairs under GSA Federal Supply Schedule contracts (FSS-61-IB). The vendor is self-certified as a small disadvantaged business and competes entirely full-and-open, with no set-asides across its prime footprint. United Therapeutics has no subcontracting presence in the federal space; all 948 recent awards are prime contracts or parent vehicles issued directly to the company.

United Therapeutics' federal customer base is heavily concentrated within the VA. The Department of Veterans Affairs National Acquisition Center and VA Veterans Health Administration Veterans Integrated Service Networks (VISNs) account for 98% of combined potential value across the award footprint. Within that, VISN 5 (Kentucky and southern Indiana) anchors the order volume with 254 awards totaling $3.7 million in potential value, VISN 21 (mid-Atlantic region) holds 123 awards worth $4.1 million, and VISN 10 (Ohio, Indiana, Michigan) carries 97 awards at $2 million. The critical concentration signal appears in the top-customer-by-potential-value ranking: the VA National Acquisition Center's four awards carry $317.1 million combined potential value—nearly 52% of United Therapeutics' entire award portfolio—reflecting the vendor's single-award Blanket Purchase Agreement (BPA) with the VA's national procurement entity.

United Therapeutics holds a $207.1 million single-award BPA with the VA National Acquisition Center, awarded April 24, 2025, and expiring April 23, 2027. The BPA operates under GSA FSS-61-IB and covers four named pharmaceutical products: Unituxin, Remodulin, Tyvaso, and Orenitram. This vehicle is the primary source of United Therapeutics' federal revenue. The Pharmaceuticals and Drugs Federal Supply Schedule itself carries 641 task orders valued at $337.3 million—the overwhelming majority of delivery orders flow through this single master vehicle. Secondary parent vehicles—Federal Supply Schedule V797P5096B (288 task orders, $17.6 million), Federal Supply Schedule V797P5628X (48 task orders, $458 thousand), and a subordinate Blanket Purchase Agreement under V797P5096B (38 task orders, $2.4 million)—represent a small fraction of order activity. The concentration is extreme: the single-award BPA structure means all delivery orders go directly to United Therapeutics at pre-negotiated firm fixed prices without competition, creating a direct-award model uncommon in federal contracting.

United Therapeutics' award activity has remained relatively flat over the trailing five years, averaging 55 awards annually (2022: 54, 2023: 62, 2024: 66, 2025: 46, 2026: 48 through mid-July). Combined potential value across all 948 awards totals $611.3 million; however, only $23.6 million (4%) has been obligated, reflecting the indefinite-delivery nature of the BPA ceiling and the small per-order values of most delivery orders (typically ranging from $14,000 to $35,000). A recompete cliff is not a material risk signal: only two awards carry completion dates within the next twenty-four months, valued at $126 thousand combined. The real exposure is the BPA's April 23, 2027 expiration, which represents the next substantial recompete opportunity. The vendor's non-competitive single-award posture means competitors pursuing VA pharmaceutical supply work will face a locked-out customer unless the VA restructures its procurement strategy toward multiple-award competition.

United Therapeutics' capability portfolio is narrowly focused: pharmaceutical manufacturing and supply of four specialty therapeutics for pulmonary arterial hypertension and oncology conditions, sold exclusively to the VA through delivery orders placed by individual Veterans Integrated Service Networks and the national acquisition center. Representative work includes the $207.1 million national BPA covering Tyvaso formulations (0.6 mg/ml starter kits, 0.6 mg/ml refill kits, 16/32/48 mcg titration kits, 48 mcg kits, 64 mcg kits, and 80 mcg doses), Remodulin (5 mg/ml injectable vials with dilution kits), Orenitram (oral tablets), and Unituxin (chemotherapy agent). Individual delivery orders under the BPA and FSS-61-IB schedule are small and repetitive, issued by VISNs across more than twenty states to individual VA medical facilities (Baltimore VA Medical Center, Huntington VA Medical Center, Puget Sound VA, and others). Performance locations are split between United Therapeutics' manufacturing facility in Bartlett, Tennessee and its corporate headquarters in Silver Spring, Maryland. A single bulk-order delivery under VISN 20 in 2023 carried a $191 thousand value; most other orders cluster between $14,000 and $35,000. The vendor has no named subsidiaries active in federal contracting, though Revivicor, Inc., a for-profit subsidiary, is listed in the corporate structure block but carries no federal awards in the source data.

The vendor operates under a parent corporation structure; the source identifies Revivicor, Inc. as a subsidiary but provides no detail on its role or separate federal contracting footprint. The awards indexed to "United Therapeutics Corp" appear to represent the consolidated prime footprint with no sub-award activity, suggesting all federal revenue flows through the parent entity's direct contracts.